Pimozide - In a controlled research study, a solitary dose of pimozide 2 milligrams coadministered with citalopram 40 mg provided daily for 11 days was related to a mean boost in QTc worths of around 10 msec contrasted to pimozide offered alone. Citalopram did not modify the mean AUC or Cmax of pimozide. The system of this pharmacodynamic communication is not recognized.Buy Citalopram 20 mg. Citalopram 60 mg.
Theophylline - Combined management of citalopram (40 mg/day for 21 days) as well as the CYP1A2 substrate theophylline (solitary dosage of 300 mg) did not impact the pharmacokinetics of theophylline. The impact of theophylline on the pharmacokinetics of citalopram was not reviewed.
Sumatriptan - There have been rare postmarketing reports describing people with weakness, incoordination, and also hyperreflexia belowing using a SSRI as well as sumatriptan. If concomitant treatment with sumatriptan as well as an SSRI (e. g. fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) is clinically warranted, suitable observation of the individual is suggested.
Warfarin - Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was enhanced by 5 %, the medical value of which is unknown.
Carbamazepine - Combined management of citalopram (40 mg/day for 14 days) and also carbamazepine (titrated to 400 mg/day for 35 days) did not substantially have an effect on the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, provided the enzyme-inducing residential properties of carbamazepine, the probability that carbamazepine could enhance the clearance of citalopram should be considered if the two medications are coadministered.